Geron Corporation ( GERN ) could have multiple clinical readouts in 2026, serving as a potential catalyst beyond how the company performs commercially with Rytelo (imetelstat). When I last wrote about GERN in January, I rated the name aScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I ...

Almitas Capital LLC bought a new position in Geron Corporation (NASDAQ:GERN – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 946,323 shares of the biopharmaceutical company’s stock, valued at approximately $1,296,000. Almitas Capital LLC owned about 0.15% of Geron at the end of the most recent reporting period. Get Geron alerts: A number of other hedge funds and other institutional investors also re ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Core Insights - Geron is focusing on the commercialization of imetelstat, a drug aimed at lower-risk MDS patients, which is seen as a significant opportunity for the company [3] - In its first full commercial year, Geron reported sales of $184 million, indicating a strong market entry [4] Company Strategy - The company is refining its commercialization plan to reach more patients effectively [3] - The leadership believes that the drug has the potential to make a meaningful difference in patient outcomes [3] Leadership Experience - The CEO, Harout Semerjian, has over 30 years of experience in the pharmaceutical and biotech industries, particularly in hematology and oncology [3]

Geron (NasdaqGS:GERN) FY Conference March 10, 2026 10:30 AM ET Company ParticipantsHarout Semerjian - President and CEOJoseph Eid - EVP of Research and Development and Chief Medical OfficerConference Call ParticipantsNicole Germino - AnalystNicole GerminoGood morning, everyone. I'm Nicole Germino, one of the biopharma investment bankers here at Barclays, and today we are joined by Harout Semerjian, President and CEO, and Joseph Eid, Executive Vice President of Research and Development and CMO of Geron. Than ...

Geron (NasdaqGS: GERN) FY Conference Summary Company Overview - Geron is a commercial-stage biotechnology company specializing in a novel class of telomerase inhibitors, with its first asset, RYTELO, now on the market [4][6]. Financial Performance - RYTELO achieved $184 million in its first full year of commercial sales [4]. - The company projects revenue growth for 2026, with guidance set between $220 million and $240 million, indicating a significant increase from approximately $190 million in 2025 [6][10]. Growth Strategy - The growth strategy focuses on execution to help more patients, particularly in the second-line treatment for low-risk MDS (Myelodysplastic Syndromes) patients [5][10]. - Internal refinements include streamlining operations and enhancing messaging to effectively reach community settings, where 80% of the business occurs [8][9]. - The company is investing in digital marketing and promotional efforts to expand its reach [8]. Market Dynamics - The low-risk MDS market is evolving, with increased use of luspatercept in frontline settings, which is beneficial for RYTELO as it positions itself as a preferred second-line agent according to updated NCCN guidelines [9][46]. - The second-line market opportunity in the U.S. is estimated at around 8,000 patients [10]. Key Performance Indicators (KPIs) - Demand growth is a critical metric, with a reported 9% growth in the last quarter [16]. - The company tracks new accounts ordering RYTELO and the percentage of patients in first-line and second-line settings, which currently stands at about 30% [17]. Community Engagement - The company emphasizes the importance of engaging community physicians to increase RYTELO prescriptions, particularly for patients transitioning from luspatercept [36][49]. - Scientific engagement and publications are being utilized to build physician confidence in prescribing RYTELO [36]. European Market Plans - Geron has received EMA approval for RYTELO and is working on market entry strategies across various European countries, which involves navigating different funding mechanisms [69][70]. - The company aims to maximize pricing strategies in line with the innovation brought by RYTELO [70]. Upcoming Trials and Data - An interim analysis for the Phase 3 MF (Myelofibrosis) trial is expected in the second half of 2026, with a full analysis projected for H2 2028 [73][74]. - The trial focuses on overall survival for patients who have relapsed or are refractory to ruxolitinib, with a significant market opportunity in myelofibrosis [73]. Company Outlook - Geron is optimistic about its growth trajectory, with a strong cash position of $400 million, allowing for continued investment in RYTELO and future developments [82]. - The company believes that the overall story of RYTELO has been underappreciated, and it is committed to executing its plans to demonstrate the drug's value for patients [81][82].

Commercialization and Product Development - Geron Corporation's near-term prospects are wholly dependent on the successful commercialization of RYTELO (imetelstat) for lower-risk myelodysplastic syndromes (MDS) and any failure could materially affect revenue generation and profitability[11]. - The company has established commercial operations for RYTELO but has limited experience in sustaining and scaling these operations, which may impact future success[11]. - Geron faces competition from existing products and technologies, which could significantly affect the commercial viability of RYTELO[12]. - Regulatory approvals for RYTELO in the U.S. and EU are subject to post-marketing requirements, and failure to comply could lead to penalties or product withdrawal[12]. - The company may face challenges in maintaining effective sales, marketing, and distribution capabilities for RYTELO, impacting revenue generation[11]. - RYTELO (imetelstat), the company's first-in-class telomerase inhibitor, received FDA approval in June 2024 and European Commission approval in March 2025 for treating lower-risk myelodysplastic syndromes[602]. - Geron Corporation partnered with Tanner Pharma in 2025 to enhance patient access to RYTELO outside the U.S. through approved Named Patient Programs[602]. - The company began shipping RYTELO in June 2024, marking its primary source of product revenue[659]. Financial Performance - The company reported product revenue of $183.6 million for the year ended December 31, 2025, compared to $76.5 million in 2024[592]. - Total costs and operating expenses for 2025 were $252.5 million, leading to a loss from operations of $68.6 million[592]. - The net loss for the year ended December 31, 2025, was $83.5 million, with a basic and diluted net loss per share of $0.13[592]. - The comprehensive loss for 2025 was $83.5 million, compared to $174.5 million in 2024 and $183.7 million in 2023, indicating a reduction in overall losses[595]. - The company’s cash flows from operating activities showed a net cash used of $111.0 million in 2025, down from $218.6 million in 2024 and $167.7 million in 2023[600]. - The company reported accrued liabilities of $51,340,000 as of December 31, 2025, an increase from $35,549,000 in 2024, primarily due to clinical trial costs and manufacturing activities[673]. - The company’s accumulated deficit increased to $1.86 billion as of December 31, 2025, compared to $1.77 billion in 2024[591]. - The company reported stock-based compensation expenses of $26.7 million in 2025, compared to $31.2 million in 2024 and $18.5 million in 2023[600]. Cash and Liquidity - As of December 31, 2025, the fair value of Geron's cash equivalents and marketable securities was $375.6 million, including $53.9 million in cash equivalents due in less than 90 days[569]. - The company’s cash and cash equivalents were $77.6 million as of December 31, 2025, down from $79.0 million in 2024[590]. - Cash equivalents, restricted cash, and marketable securities totaled $321,648,000 as of December 31, 2025, compared to $422,069,000 in 2024, indicating a decrease in liquidity[661][663]. - The company has limited its credit and liquidity risks through an investment policy that diversifies its portfolio and reduces credit risk concentrations[569]. Debt and Financing - The company entered into a loan agreement for a 5-year senior secured term loan facility of up to $250 million, with Tranche A Loan of $125 million funded on November 1, 2024[570]. - The interest rate on the Term Loans is variable at 5.75% plus the three-month SOFR, with a SOFR floor of 3.00%, resulting in an applicable interest rate of 11.13% as of December 31, 2025[699]. - The company received an upfront payment of $125 million from Royalty Pharma in exchange for a revenue participation right, with a participation rate starting at 7.75% for U.S. net sales up to $500 million, declining to 1% for sales exceeding $1 billion[705]. - The company completed a public offering on January 10, 2023, raising net cash proceeds of $213.3 million from the sale of 68,007,741 shares at a price of $2.45 per share[714]. - A subsequent public offering on March 21, 2024, generated approximately $141 million in net cash proceeds from the sale of 41,999,998 shares at a price of $3.00 per share[715]. Inventory and Assets - As of December 31, 2025, the company had total inventory of $116.6 million, with adjustments made for slow moving and excess inventory based on future product demand[581]. - As of December 31, 2025, total inventory was $116,636,000, a significant increase from $38,714,000 in 2024, driven by raw materials, work-in-process, and finished goods[660]. - The fair value of total assets measured at fair value was $377,458,000 as of December 31, 2025, with significant contributions from commercial paper and corporate notes[667]. Legal and Regulatory Risks - The company has faced legal proceedings, including two putative securities class action lawsuits alleging misleading statements regarding the commercial potential of RYTELO, which could impact future financial performance[675]. - The company has not been able to reasonably estimate potential losses from pending lawsuits, which could materially impact consolidated financial statements[681]. - The company is subject to pricing and reimbursement regulations in the EU, which may materially affect its ability to commercialize RYTELO[12]. Restructuring and Workforce - Geron has implemented a strategic restructuring plan that may not yield anticipated savings and could disrupt business operations[12]. - The company implemented a workforce reduction in December 2025, representing approximately one-third of its workforce prior to the reduction[685]. - The severance plans provide for severance payments ranging from three to 18 months of base salary for executives upon a Change of Control Triggering Event[683]. Stock and Equity - The company’s stockholders approved an amendment in May 2023 to increase the total number of authorized shares of common stock from 675 million to 1.35 billion shares[713]. - As of December 31, 2025, a total of 98,971,971 shares of common stock have been reserved under the 2018 Equity Incentive Plan, with 51,542,796 shares available for future grants[726]. - The total intrinsic value of stock options exercised in 2025 was approximately $0.5 million, compared to $41.2 million in 2024[738]. - The weighted average estimated fair value of stock options granted in 2025 was $1.17 per share, compared to $2.05 in 2024[738]. Tax and Deferred Tax Assets - The company reported domestic net operating loss carryforwards of approximately $1.0 billion, with $561.7 million expiring between 2026 and 2037[753]. - As of December 31, 2025, the company had total deferred tax assets of $445,194,000, offset by a valuation allowance of $444,650,000[752]. - The effective tax rate for the year ended December 31, 2025, was 0.1%, reflecting the full valuation allowance against deferred tax assets[751].

Geron Corporation (NASDAQ:GERN) is one of the most promising penny stocks under $5 to buy. On February 25, Geron Corporation reported earnings results for Q4 and the full year of 2025, fueled by the commercial success of its first-in-class telomerase inhibitor, RYTELO. The company achieved $48 million in net product revenue for Q4 and $183.6 million for the full year. This growth was supported by a 9% increase in demand and the expansion of its ordering accounts to ~1,300. Strategically, Geron underwent ...

Core Viewpoint - The article emphasizes the importance of conducting thorough research and independent verification before making investment decisions, highlighting the inherent risks and volatility associated with stock investments [2][3]. Group 1 - The article provides informational content but does not serve as an exhaustive analysis of any featured company [2]. - It clarifies that the predictions and opinions presented are based on a probabilistic approach rather than absolute certainty [2]. - The author has no financial interest in the companies mentioned, ensuring an unbiased perspective [1]. Group 2 - The article stresses that past performance is not indicative of future results, cautioning readers against relying solely on historical data [3]. - It notes that the views expressed may not reflect those of the platform as a whole, indicating a diversity of opinions among contributors [3]. - The article highlights that the analysts may not be licensed or certified, which could affect the reliability of the information provided [3].

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive a ...